File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Book Chapter: Resistance to influenza neuraminidase inhibitors
| Title | Resistance to influenza neuraminidase inhibitors |
|---|---|
| Authors | |
| Issue Date | 2017 |
| Publisher | Springer |
| Citation | Resistance to influenza neuraminidase inhibitors. In Mayers, DL ... (et al) (Eds.), Antimicrobial drug resistance. Volume 1, Mechanisms of Drug Resistance (2nd ed.), p. 491-501. Cham: Springer, 2017 How to Cite? |
| Abstract | Annual epidemics and periodic pandemics caused by influenza viruses are associated with significant disease burden. Three classes of antiviral compounds, M2 ion-channel blockers (Amantadine and Rimantadine), neuraminidase (NA) inhibitors (Zanamivir, Oseltamivir, Peramivir, Laninamivir), and RNA-dependent RNA polymerase inhibitor (Favipiravir) have been approved for clinical use against influenza infections to date. The M2 ion-channel blockers effective in inhibiting proton conductivity of influenza A viruses were no longer recommended for clinical use since 2009 due to high prevalence of resistant variants among seasonal influenza A viruses of H3N2 and H1N1 subtypes. NA inhibitors are the current mainstays for influenza prophylaxis and treatment. Four approved NA inhibitors were structural-based designed to achieve specific interactions with the conserved residues at the NA enzyme site. This Chapter will discuss the resistance mechanisms for the NA inhibitors. |
| Persistent Identifier | http://hdl.handle.net/10722/244650 |
| ISBN |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Yen, H | - |
| dc.date.accessioned | 2017-09-18T01:56:30Z | - |
| dc.date.available | 2017-09-18T01:56:30Z | - |
| dc.date.issued | 2017 | - |
| dc.identifier.citation | Resistance to influenza neuraminidase inhibitors. In Mayers, DL ... (et al) (Eds.), Antimicrobial drug resistance. Volume 1, Mechanisms of Drug Resistance (2nd ed.), p. 491-501. Cham: Springer, 2017 | - |
| dc.identifier.isbn | 978-3-319-46716-0 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/244650 | - |
| dc.description.abstract | Annual epidemics and periodic pandemics caused by influenza viruses are associated with significant disease burden. Three classes of antiviral compounds, M2 ion-channel blockers (Amantadine and Rimantadine), neuraminidase (NA) inhibitors (Zanamivir, Oseltamivir, Peramivir, Laninamivir), and RNA-dependent RNA polymerase inhibitor (Favipiravir) have been approved for clinical use against influenza infections to date. The M2 ion-channel blockers effective in inhibiting proton conductivity of influenza A viruses were no longer recommended for clinical use since 2009 due to high prevalence of resistant variants among seasonal influenza A viruses of H3N2 and H1N1 subtypes. NA inhibitors are the current mainstays for influenza prophylaxis and treatment. Four approved NA inhibitors were structural-based designed to achieve specific interactions with the conserved residues at the NA enzyme site. This Chapter will discuss the resistance mechanisms for the NA inhibitors. | - |
| dc.language | eng | - |
| dc.publisher | Springer | - |
| dc.relation.ispartof | Antimicrobial drug resistance. Volume 1, Mechanisms of Drug Resistance (2nd ed.) | - |
| dc.title | Resistance to influenza neuraminidase inhibitors | - |
| dc.type | Book_Chapter | - |
| dc.identifier.email | Yen, H: hyen@hku.hk | - |
| dc.identifier.authority | Yen, H=rp00304 | - |
| dc.identifier.doi | 10.1007/978-3-319-46718-4_32 | - |
| dc.identifier.hkuros | 275799 | - |
| dc.identifier.spage | 491 | - |
| dc.identifier.epage | 501 | - |
| dc.publisher.place | Cham | - |